Transmedics Group Stock News

Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.

Here's why our roundtable likes Intellia Therapeutics, Doximity, and TransMedics.

TransMedics has started 2022 with great operating momentum. Strong results have resulted in shares recovering after a big selloff early this year.

Transmedics Group, Inc. (NASDAQ:TMDX ) Q1 2022 Earnings Conference Call May 3, 2022 5:00 PM ET Company Participants Brian Johnston - Gilmartin Group Waleed Hassanein - President and CEO Stephen Gordon

TransMedics (TMDX) delivered earnings and revenue surprises of -8.57% and 55.34%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

TransMedics (TMDX) delivered earnings and revenue surprises of -8.57% and 55.34%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ANDOVER, Mass. , April 19, 2022 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end

TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase

TransMedics (TMDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

TransMedics (TMDX) delivered earnings and revenue surprises of -6.98% and 26.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Transmedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q4 2021 Results - Earnings Call Transcript

Pacific Biosciences (PACB) delivered earnings and revenue surprises of -7.14% and 0.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Transmedics Group Inc (TMDX) shares closed today at 0.8% above its 52 week low of $17.25, giving the company a market cap of $482M. The stock is currently down 9.3% year-to-date, down 2.1% over the past 12 months, and down 22.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 10.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 8.5% lower than its 5-day moving average, 14.1% lower than its 20-day moving average, and 33.8% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 170.0% The company's stock price performance over the past 12 months beats the peer average by -76.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

ANDOVER, Mass. , Dec. 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-